Epilepsy is one of the serious disorders with no age, sex or racial boundaries. Epilepsy imposes a large economic burden on health care systems of countries. There is also a hidden burden associated with stigma and discrimination against the patient and even their family in the community, workplace, and home. In general, the patients with epilepsy suffer severe emotional distress, behavioral disorders and extreme social isolation. Epilepsy is usually associated with recurrent seizures. This implies that epilepsy is an ancient disorder; indeed, in all civilizations it can be traced as far back as medical records exist. In fact, epilepsy is a disorder that can occur in all mammalian species, probably more frequently as brains have become more complex. Epilepsy is also remarkably uniformly distributed around the world. Among the reported potential agents to treat the epilepsy, sulphonamides are important and their significance cannot be ignored. Sulphonamides are of high attention for various pharmacological importance, as it is reported for chiefly anticonvulsant antitubercular and antimicrobial activities. For all these activities, the suphonamide derivatives are reported with multiple scaffolds such as Sulfonamides incorporating Valproyl derivatives, Sulfamates, Sulfamides, Thiazolidin derivatives, Aminobenzamides, Beta-Ketosulfonamide etc.